The effects of IL-17A and anti-IL-17A treatment have also been proved in asthma, rheumatoid arthritis, multiple sclerosis, transplant rejection, and inflammatory bowel disease (Chen and Kolls, 2017). This evidence concerns the gene IL17A and multiple sclerosis.